最强主线回归？AH创新药联袂大涨，多股飙升逾10%！高弹性港股通创新药ETF（520880）放量冲刺4%

Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a significant resurgence, with both A-shares and Hong Kong stocks showing strong performance on September 5 [1][3] - A-shares of innovative drug companies collectively surged, with notable increases such as Zai Lab rising over 15% and 3SBio increasing by more than 11% [1] - Hong Kong stocks in the innovative drug sector outperformed, with 3SBio up over 15% and CanSino Biologics-B rising over 12%, indicating robust market interest [1] Group 2 - Guosen Securities reported that the innovative drug sector has performed well in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies [3] - The domestic innovative drug market is expected to grow rapidly, with new products likely to achieve commercial value quickly due to national policies encouraging innovation [3] - According to Dongfang Securities, the performance of innovative drugs is projected to be outstanding as domestic products enter the commercialization phase and overseas potential is realized [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown exceptional performance, with a year-to-date increase of 118.95%, leading among similar indices [3][4] - The index for the Hong Kong Stock Connect Innovative Drug ETF will undergo a "purification" process on September 8, focusing solely on innovative drug research and development companies [5] - Historical performance of the index shows fluctuations, with annual declines in previous years, but the current trend indicates a strong recovery [5]